市場調査レポート

商品コード

1701011

次世代がん診断薬の市場規模、シェア、成長分析、製品・サービス別、技術別、がんタイプ別、用途別、最終用途別、地域別-2025年～2032年の産業予測

Next Generation Cancer Diagnostics Market Size, Share, and Growth Analysis, By Product and Services, By Technology, By Cancer Type, By Application, By End Use, By Region - Industry Forecast 2025-2032

出版日: 2025年04月02日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 789,170円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 923,180円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,057,190円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.90円

全表示
概要
目次

概要

サンプル依頼リストに入れる

次世代がん診断薬の2023年の市場規模は159億米ドルで、2024年の188億4,000万米ドルから2032年には732億6,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは18.5%で推移する展望です。

同市場は、先進的な診断機器、キット、試薬の商品化により、従来のラボ検査から迅速なポイントオブケア検査へと移行しつつあります。この進化は、特に個別化ゲノム医療に貴重な機会をもたらすコンパニオン診断薬の台頭とともに、市場の成長を大きく後押ししています。非ホジキンリンパ腫やその他の有名ながんの症例が近年54万4,000件以上報告されていることからも明らかなように、世界のがん罹患率の増加は、これらの革新的な診断ツールに対する需要を強調しています。がんは世界第2位の死亡原因であり、年間960万人以上が死亡しています。その結果、次世代診断薬の開発は、厳しい課題に直面する世界の医療情勢の中で、精度と価格を向上させ、早期発見と患者の転帰改善を促進しています。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他の欧州
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主要市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022～2024年）
  主要企業プロファイル
  - Roche Holding AG（スイス）
  - Thermo Fisher Scientific Inc.（米国）
  - Illumina, Inc.（米国）
  - Abbott Laboratories（米国）
  - QIAGEN N.V.（Germany/Netherlands）
  - Agilent Technologies, Inc.（米国）
  - Bio-Rad Laboratories, Inc.（米国）
  - Becton, Dickinson and Company（BD）（米国）
  - Myriad Genetics, Inc.（米国）
  - Guardant Health, Inc.（米国）
  - Exact Sciences Corporation（米国）
  - Danaher Corporation（米国）
  - Siemens Healthineers AG（ドイツ）
  - Hologic, Inc.（米国）
  - GE Healthcare（米国）
  - Novartis AG（スイス）
  - Merck KGaA（ドイツ）
  - Sysmex Corporation（日本）
  - Invitae Corporation（米国）

結論と提言

Product Code: SQMIG35A2226

Next Generation Cancer Diagnostics Market size was valued at USD 15.9 billion in 2023 and is poised to grow from USD 18.84 billion in 2024 to USD 73.26 billion by 2032, growing at a CAGR of 18.5% during the forecast period (2025-2032).

The market is transitioning from traditional laboratory testing to rapid point-of-care testing, driven by the commercialization of advanced diagnostic devices, kits, and reagents. This evolution is significantly boosting market growth, particularly with the rise of companion diagnostics, which present valuable opportunities in personalized genomic medicine. The increasing global cancer prevalence underscores the demand for these innovative diagnostic tools, as evidenced by over 544,000 cases of non-Hodgkin lymphoma and other high-profile cancers reported in recent years. With cancer as the second-leading cause of mortality worldwide, highlighting more than 9.6 million deaths annually, the need for advanced cancer detection is critical. Consequently, the development of next-generation diagnostics is enhancing accuracy and affordability, promoting early detection and improved patient outcomes amid a global healthcare landscape facing severe challenges.

Top-down and bottom-up approaches were used to estimate and validate the size of the Next Generation Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Next Generation Cancer Diagnostics Market Segments Analysis

Global Next Generation Cancer Diagnostics Market is segmented by Product and Services, Technology, Cancer Type, Application, End Use and region. Based on Product and Services, the market is segmented into Products and Services. Based on Technology, the market is segmented into Next-generation sequencing (NGS), Polymerase chain reaction (PCR), DNA microarrays, Multiplexing and Other technologies. Based on Cancer Type, the market is segmented into Breast cancer, Lung cancer, Colorectal cancer, Prostate cancer, Cervical cancer, Liver cancer and Other cancer types. Based on Application, the market is segmented into Screening and early detection, Prognostics and monitoring, Therapy selection, Recurrence monitoring and Other applications. Based on End Use, the market is segmented into Hospitals & clinics, Diagnostic laboratories, Academic & research institutions and Other end users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Next Generation Cancer Diagnostics Market

The increasing demand for personalized medicine significantly contributes to the expansion of the next generation cancer diagnostics market. Personalized medicine focuses on customizing treatments according to each patient's unique genetic makeup and specific characteristics, ensuring a more effective approach to cancer care. Advanced diagnostics tools are essential in this context, as they can pinpoint patients who are most likely to respond positively to tailored therapies. By facilitating the identification of suitable candidates for these individualized treatments, next generation cancer diagnostics not only enhance treatment efficacy but also drive innovation and growth within the healthcare sector.

Restraints in the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market faces significant challenges stemming from unclear reimbursement policies and the slow evolution of these frameworks. This ambiguity hinders the widespread adoption of innovative technologies, complicating the decision-making process for healthcare providers and patients regarding the justification of expenses linked to such diagnostic tests. Furthermore, reimbursement policies differ greatly across various countries, regions, and healthcare systems, leading to a fragmented landscape. In many instances, these policies are still under development, reflecting an absence of consensus on the appropriate reimbursement strategies for these advanced diagnostic solutions, which ultimately restricts their integration into clinical practice.

Market Trends of the Next Generation Cancer Diagnostics Market

The Next Generation Cancer Diagnostics market is increasingly shifting towards liquid biopsy tests, reflecting a significant trend in oncology diagnostics. These minimally invasive tests, which utilize blood, urine, and other bodily fluids to identify cancerous cells and biomarkers, are gaining traction due to their cost-effectiveness and ability to deliver rapid, reliable results. As healthcare providers seek more efficient diagnostic tools, the adoption of liquid biopsies is expected to grow, prompting substantial investments from biotech firms and research institutions. This evolving landscape is anticipated to reshape cancer detection and monitoring, driving innovation and improving patient outcomes in oncology.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis

Global Next Generation Cancer Diagnostics Market Size by Product and Services & CAGR (2025-2032)

Market Overview
Products
- Instruments
- Kits & consumables
Services

Global Next Generation Cancer Diagnostics Market Size by Technology & CAGR (2025-2032)

Market Overview
Next-generation sequencing (NGS)
Polymerase chain reaction (PCR)
DNA microarrays
Multiplexing
Other technologies

Global Next Generation Cancer Diagnostics Market Size by Cancer Type & CAGR (2025-2032)

Market Overview
Breast cancer
Lung cancer
Colorectal cancer
Prostate cancer
Cervical cancer
Liver cancer
Other cancer types

Global Next Generation Cancer Diagnostics Market Size by Application & CAGR (2025-2032)

Market Overview
Screening and early detection
Prognostics and monitoring
Therapy selection
Recurrence monitoring
Other applications

Global Next Generation Cancer Diagnostics Market Size by End Use & CAGR (2025-2032)

Market Overview
Hospitals & clinics
Diagnostic laboratories
Academic & research institutions
Other end users

Global Next Generation Cancer Diagnostics Market Size & CAGR (2025-2032)

North America (Product and Services, Technology, Cancer Type, Application, End Use)
- US
- Canada
Europe (Product and Services, Technology, Cancer Type, Application, End Use)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product and Services, Technology, Cancer Type, Application, End Use)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product and Services, Technology, Cancer Type, Application, End Use)
- Brazil
- Rest of Latin America
Middle East & Africa (Product and Services, Technology, Cancer Type, Application, End Use)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Abbott Laboratories (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
QIAGEN N.V. (Germany/Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agilent Technologies, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Becton, Dickinson and Company (BD) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Myriad Genetics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Exact Sciences Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Danaher Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siemens Healthineers AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hologic, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GE Healthcare (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Invitae Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

次世代がん診断薬の市場規模、シェア、成長分析、製品・サービス別、技術別、がんタイプ別、用途別、最終用途別、地域別-2025年～2032年の産業予測

Next Generation Cancer Diagnostics Market Size, Share, and Growth Analysis, By Product and Services, By Technology, By Cancer Type, By Application, By End Use, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と展望

主要市場の考察

次世代がん診断薬市場規模：製品・サービス別&CAGR（2025～2032年）

次世代がん診断薬市場規模：技術別&CAGR（2025～2032年）

次世代がん診断薬市場規模：がんタイプ別&CAGR（2025～2032年）

次世代がん診断薬市場規模：用途別&CAGR（2025～2032年）

次世代がん診断薬市場規模：最終用途別&CAGR（2025～2032年）

次世代がん診断薬市場規模&CAGR（2025～2032年）